BSGM_OUT_1 [2025-04-28 12:30:39 -0400] 4472 Bytes | 1089 tokens | Cum: 1089 tkns (13.61% of 8k)
==========================================================================

Listen up, partner—it's 12:30 PM on Mon Apr 28, 2025, and I’m revved up about BioSig Technologies (BSGM), climbing from $0.9200 to $1.11. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: BioSig Technologies (BSGM)
IPO: 2014-09-22 (10 Years Ago)
Market Cap: $14,066,440
Shares Outstanding: 24,250,000
Industry: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange: XNAS
Description: BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.

Here’s a list of headlines for BioSig Technologies:

Apr-24-25 12:00PM - Biosig Technologies (BSGM) Upgraded to Buy: What Does It Mean for the Stock?
Mar-26-25 09:00AM - BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market
Jan-22-25 07:00AM - OTC Markets Group Announces Quarterly Index Performance and Rebalancing
Nov-13-24 03:14PM - BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Oct-22-24 03:13PM - BioSig Technologies Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
Aug-01-24 04:32AM - BioSig intends to acquire Neuro-Kinesis assets
Jul-31-24 09:45AM - BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
Jul-25-24 01:57PM - BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-22T12:00:00Z - OTC Markets Group Announces Quarterly Index Performance and Rebalancing
B2 - 2024-06-10T13:45:00Z - BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
B3 - 2024-05-21T15:10:00Z - BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
B4 - 2024-05-03T16:22:00Z - BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent  
B5 - 2024-04-30T18:03:00Z - BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
B6 - 2024-04-16T18:17:57Z - Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for BioSig Technologies (BSGM).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

BSGM_OUT_3 [2025-04-28 12:30:39 -0400] 912 Bytes | 247 tokens | Cum: 1338 tkns (16.73% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/21/2885826/22558/en/BioSig-Technologies-Chief-Executive-Officer-Mr-Anthony-Amato-Issues-the-Following-Letter-to-Shareholders.htmlWestport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_5 [2025-04-28 12:30:40 -0400] 1039 Bytes | 306 tokens | Cum: 1646 tkns (20.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T17:05:54Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO),...
A2 - 2025-04-21T14:03:37Z - Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - BioSig Technologies (...
A3 - 2025-04-16T21:05:42Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Aspira Womens Health (NASDAQ:AWH)...
A4 - 2025-04-15T21:05:49Z - 12 Health Care Stocks Moving In Tuesday's After-Market Session - Cue Biopharma (NASDAQ:CUE), BioSig ...
A5 - 2025-04-14T21:06:19Z - 12 Health Care Stocks Moving In Monday's After-Market Session - BioSig Technologies (NASDAQ:BSGM), B...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BSGM_OUT_7 [2025-04-28 12:30:41 -0400] 1181 Bytes | 348 tokens | Cum: 1996 tkns (24.95% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO), BioSig Technologies (NASDAQ:BSGM)**Date: 2025-04-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44989024/12-health-care-stocks-moving-in-thursdays-intraday-sessionGainers CERo Therapeutics Hldgs CERO stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. TransCode Therapeutics RNAZ shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. Zhengye Biotechnology ZYBT shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. Community Health Sys CYH shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As pe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_9 [2025-04-28 12:30:41 -0400] 1181 Bytes | 344 tokens | Cum: 2342 tkns (29.28% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): r the press release, Q1 earnings came out yesterday. BioSig Technologies BSGM shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. Jaguar Health JAGX shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. Losers NuCana NCNA shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. Intensity Therapeutics INTS shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. Ensysce Biosciences ENSC shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. Metsera MTSR stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. Catheter Precision VTAK stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. Plus Therapeutics P

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_11 [2025-04-28 12:30:42 -0400] 1181 Bytes | 386 tokens | Cum: 2730 tkns (34.12% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): STV shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGMBioSig Technologies Inc$0.780021.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum15.59Growth84.23Quality-Value2.67Price TrendShortMediumLongOverviewCEROCERo Therapeutics Holdings Inc$1.1240.1%CYHCommunity Health Systems Inc$3.0224.2%ENSCEnsysce Biosciences Inc$3.08-16.2%INTSIntensity Therapeutics Inc$0.9900-23.9%JAGXJaguar Health Inc$8.1021.4%MTSRMetsera Inc$20.02-15.1%NCNANuCana PLC$0.6587-26.0%PSTVPlus Therapeutics Inc$0.8828-10.2%RNAZTransCode Therapeutics Inc$0.380321.1%VTAKCatheter Precision Inc$0.3038-5.06%ZYBTZhengye Biotechnology

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_13 [2025-04-28 12:30:43 -0400] 357 Bytes | 107 tokens | Cum: 2839 tkns (35.49% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): Holding Ltd$9.8425.8%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_15 [2025-04-28 12:30:43 -0400] 1076 Bytes | 285 tokens | Cum: 3126 tkns (39.07% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-15 10-K ITEM 7 MGT S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

Management s Discussion and Analysis of Fin Cond and Results of Oper is intended to provide a reader of our financial statements with a narrative from the perspective ...

S2 - 2025-03-05 8-K Item 1.01 Entry into a Material Definitive Agrmt

On March 5, 2025, BioSig Technologies, Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain accredited investors (the Investors), pursuant to which the Company sold to the Inve...

S3 - 2025-03-03 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On February 28, 2025 (the Effective Date), BioSig Technologies, Inc.. (the Company) entered into a Equity Subscription Agrmt (the Subscription Agrmt) with Lind Global Fund III, LP (the Investor).

Pursuant to the S...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BSGM_OUT_17 [2025-04-28 12:30:44 -0400] 1181 Bytes | 238 tokens | Cum: 3366 tkns (42.08% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7 MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity, and certain other factors that may affect our future results. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and the related notes thereto that are included in this Form 10-K. In addition to historical information, the following discussion and analysis includes forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statement

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_19 [2025-04-28 12:30:46 -0400] 1181 Bytes | 242 tokens | Cum: 3610 tkns (45.12% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): s. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the section entitled Risk Factors. See Note on Forward-Looking Statements.

Overview

Business Overview

BioSig Technologies is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.

The PURE EP Platform enables electrophysiologists to acquire raw signal data in real-timeabsent of unnecessary noise or interferenceto maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_21 [2025-04-28 12:30:46 -0400] 1181 Bytes | 259 tokens | Cum: 3871 tkns (48.39% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ertinent.

By capturing critical cardiac signalseven the most complexPURE EP is designed to enhance clinical decision-making and improve clinical workflow for all types of arrhythmias, even the most challenging procedures for cardiac arrhythmias, like ventricular tachycardia (VT) and atrial fibrillation (AF).

BioSig has pivoted from a focus on commercial distribution of hardware to the research and development of novel software algorithms that advance our understanding of mechanisms and tissue characteristics. Data collection began in December 2023 and is ongoing. Despite its rapid adoption, there is room to improve the long-term outcomes of pulsed field ablation (PFA). Our primary focus is aimed at improving the specificity of PFA treatment and improving clinical outcomes.

Our owned patent portfolio now includes 41 issued/allowed utility patents (29 utility patents where BioSig is

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_23 [2025-04-28 12:30:47 -0400] 1181 Bytes | 252 tokens | Cum: 4125 tkns (51.56% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): at least one of the applicants). Thirty one additional U.S. and foreign utility patent applications are pending covering various aspects of our PURE EP System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures (31 U.S. and foreign utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have one U.S. patent and one U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents, which cover various features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30 design patents where BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional worldwide utility patent applications from Mayo Foundation for Medical Education and R

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_25 [2025-04-28 12:30:48 -0400] 1181 Bytes | 284 tokens | Cum: 4411 tkns (55.14% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): esearch that are pending (12 issued/allowed patents and 9 applications where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.

##TABLE_START 51 ##TABLE_END

Recent Developments

Issuance of debt

On March 7, 2024, the Company issued a promissory note to an investor and related party (10% plus shareholder) for $500,000. The Company designated its 12% note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the Securities Act).

The note was due March 7, 2026. The Company promised to pay interest in cash on the unpaid principal amount of this note at a rate per annum equal to twelve percent (12%), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided therein. The Note contained customary events of default.

The Com

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_27 [2025-04-28 12:30:49 -0400] 790 Bytes | 199 tokens | Cum: 4612 tkns (57.65% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): pany was able to prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty. On May 1, 2024, we converted the promissory note and related accrued interest of $509,165 into 348,624 shares of common stock and warrants to purchase 174,312 shares of common stock at $1.398 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance.

Private Placements

On January ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BSGM_OUT_29 [2025-04-28 12:30:56 -0400] 5932 Bytes | 1560 tokens | Cum: 6174 tkns (77.18% of 8k)
==========================================================================

This is our set of metrics for BioSig Technologies.
Please analyze the numbers.

+---------------------+----------------------+------------------------+------------------------+
| Volume: 305,050 | Perf Month: 74.76% | Option/Short: No / Yes | Sales Y/Y TTM: 122.22% |
+---------------------+----------------------+------------------------+------------------------+
| Avg Volume: 300.46K | Perf Quarter: 12.46% | Short Float: 2.26% | ROE: -8041.70% |
+---------------------+----------------------+------------------------+------------------------+
| Rel Volume: 2.27 | Index: - | Short Ratio: 1.42 | ROI: - |
+---------------------+----------------------+------------------------+------------------------+
| RSI (14): 73.52 | Market Cap: 26.19M | Short Interest: 0.43M | Sales Surprise: - |
+---------------------+----------------------+------------------------+------------------------+
| ATR (14): 0.13 | Shs Outstand: 24.25M | Beta: 0.02 | EPS Surprise: 58.82% |
+---------------------+----------------------+------------------------+------------------------+
| SMA20: 72.72% | Shs Float: 18.86M | Sales Q/Q: 8.33% | P/E: - |
+---------------------+----------------------+------------------------+------------------------+
| SMA50: 50.67% | Inst Own: 19.33% | Sales past 5Y: -1.33% | Earnings: Feb 26 |
+---------------------+----------------------+------------------------+------------------------+
| SMA200: 26.45% | Insider Own: 22.25% | Employees: 5 | |
+---------------------+----------------------+------------------------+------------------------+
| Perf Week: 102.06% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+----------------------+------------------------+------------------------+

The next section covers any insider trading by BioSig Technologies officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 14000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3415000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.11
Average Volume: 196422.15
30-Day High: 1.11
30-Day Low: 0.4778

[Detailed Financials: Q1 2024]
- Total Assets: $1,589,000.00
- Total Liabilities: $5,792,000.00
- Total Equity: $-4,308,000.00
- Current Assets: $740,000.00
- Current Liabilities: $5,232,000.00

[Income Statement: Q1 2024]
- Revenue: $14,000.00
- Net Income: $-3,415,000.00
- Gross Profit: N/A
- Operating Income: $-3,437,000.00
- Earnings Per Share (EPS): -0.36

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $0.00

[Detailed Financials: FY 2023]
- Total Assets: $1,798,000.00
- Total Liabilities: $4,685,000.00
- Total Equity: $-2,992,000.00
- Current Assets: $528,000.00
- Current Liabilities: $4,582,000.00

[Income Statement: FY 2023]
- Revenue: $18,000.00
- Net Income: $-28,690,000.00
- Gross Profit: $18,000.00
- Operating Income: $-28,512,000.00
- Earnings Per Share (EPS): -3.95

[Cash Flow Statement: FY 2023]
- Net Cash Flow: $-167,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of BioSig Technologies (BSGM).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about BioSig Technologies.

2) MARKET_SCORE[]
This conversation was initiated because BSGM is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for BSGM.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, BSGM could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect BSGM to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of BioSig Technologies.

11) ETHICAL_RATING[]
Rate BioSig Technologies’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of BioSig Technologies.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

BSGM_IN_31 [2025-04-28 12:30:57 -0400] 126 Bytes | 29 tokens | Cum: 6425 tkns (80.31% of 8k)
==========================================================================

====================================
[2025-04-28 12:30:57] # Analysis Completed
Elapsed Time: 18.59 seconds